publication venue for
- Corrigendum to "Trends in insurance coverage and treatment among persons with opioid use disorders following the affordable care act" [Drug Alcohol. Depend. 179 (2017) 271-274]. 2017
- An economic analysis of community costs incurred to implement the communities that HEAL intervention to reduce opioid overdose deaths in four states.. 272. 2025
- The burden of alcohol and substance use disorders in adolescents and young adults.. 266. 2024
- Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.. 263. 2024
- Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study.. 261. 2024
- Offering nurse care management for opioid use disorder in primary care: Impact on emergency and hospital utilization in a cluster-randomized implementation trial.. 261. 2024
- Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.. 259. 2024
- Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004-2019.. 257. 2024
- Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts.. 241. 2022
- State prescribing cap laws' association with opioid analgesic prescribing and opioid overdose.. 240. 2022
- Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020.. 232. 2022
- Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.. 232. 2022
- Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.. 232. 2022
- Psychosocial and health problems associated with alcohol use disorder and cannabis use disorder in U.S. adults.. 229. 2021
- The association between prescription opioid dispensing and opioid-related morbidity and mortality in Ontario, Canada: an ecological study of public health units.. 227. 2021
- Estimating the community prevalence, child traits, and maternal risk factors of fetal alcohol spectrum disorders (FASD) from a random sample of school children.. 227. 2021
- Substance use and suicide outcomes among self-injured trauma patients.. 226. 2021
- Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.. 225. 2021
- The role of stigma in U.S. primary care physicians' treatment of opioid use disorder.. 221. 2021
- Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City.. 221. 2021
- The cost of opioid use disorder and the value of aversion.. 217. 2020
- Impact of state-level cannabis legalization on poly use of alcohol and cannabis in the United States, 2004-2017.. 218. 2020
- Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study.. 217. 2020
- Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.. 216. 2020
- Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.. 215. 2020
- Cannabis use among US adults with anxiety from 2008 to 2017: The role of state-level cannabis legalization.. 214. 2020
- Implementation and enforcement of state opioid prescribing laws.. 213. 2020
- Cannabis use during pregnancy in the United States: The role of depression.. 210. 2020
- Low overdose responding self-efficacy among adults who report lifetime opioid use.. 201. 2019
- Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.. 200. 2019
- Recreational marijuana legalization and prescription opioids received by Medicaid enrollees.. 194. 2018
- Transitions through stages of alcohol involvement: The potential role of mood disorders.. 189. 2018
- Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.. 185. 2018
- Trends in insurance coverage and treatment among persons with opioid use disorders following the Affordable Care Act.. 179. 2017
- Substance use and STI acquisition: Secondary analysis from the AWARE study.. 169. 2016
- Primary care physicians' perspectives on the prescription opioid epidemic.. 165. 2016
- Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial.. 161. 2016
- Mortality among heroin users and users of other internationally regulated drugs: A 27-year follow-up of users in the Epidemiologic Catchment Area Program household samples.. 156. 2015
- An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness.. 153. 2015
- Antiretroviral therapy for prevention of HIV transmission: potential role for people who inject drugs in Central Asia.. 132 Suppl 1. 2013
- The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial.. 128. 2012
- The relationship between recreational gambling and substance abuse/dependence: data from a nationally representative sample.. 100. 2008
- Illicit drug use in young adults and subsequent decline in general health: the Coronary Artery Risk Development in Young Adults (CARDIA) Study.. 88. 2006
- The Kreek-McHugh-Schluger-Kellogg scale: a new, rapid method for quantifying substance abuse and its possible applications.. 69. 2003
- Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects.. 54. 1999
- Serum prolactin correlates with depressed mood during alcohol withdrawal.. 17. 1986
- Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. 2022
- Mindfulness meditation improves emotion regulation and reduces drug abuse. 2016
- Short term health-related quality of life improvement during opioid agonist treatment. 2015